Cue Biopharma (CUE) Competitors $1.61 -0.14 (-8.00%) (As of 10/31/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CUE vs. AVIR, URGN, STRO, BTMD, PRQR, HRTX, IMMP, GNFT, CDXC, and EDITShould you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Atea Pharmaceuticals (AVIR), UroGen Pharma (URGN), Sutro Biopharma (STRO), biote (BTMD), ProQR Therapeutics (PRQR), Heron Therapeutics (HRTX), Immutep (IMMP), Genfit (GNFT), ChromaDex (CDXC), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry. Cue Biopharma vs. Atea Pharmaceuticals UroGen Pharma Sutro Biopharma biote ProQR Therapeutics Heron Therapeutics Immutep Genfit ChromaDex Editas Medicine Cue Biopharma (NASDAQ:CUE) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings. Do analysts prefer CUE or AVIR? Cue Biopharma presently has a consensus target price of $5.00, indicating a potential upside of 210.56%. Atea Pharmaceuticals has a consensus target price of $6.88, indicating a potential upside of 112.35%. Given Cue Biopharma's higher possible upside, equities research analysts plainly believe Cue Biopharma is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in CUE or AVIR? 35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 7.5% of Cue Biopharma shares are owned by insiders. Comparatively, 17.8% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer CUE or AVIR? In the previous week, Cue Biopharma and Cue Biopharma both had 2 articles in the media. Cue Biopharma's average media sentiment score of 1.58 beat Atea Pharmaceuticals' score of 0.96 indicating that Cue Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, CUE or AVIR? Cue Biopharma has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Which has preferable earnings & valuation, CUE or AVIR? Cue Biopharma has higher earnings, but lower revenue than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCue Biopharma$8.30M9.44-$50.73M-$1.06-1.52Atea Pharmaceuticals$351.37M0.78-$135.96M-$2.10-1.54 Does the MarketBeat Community favor CUE or AVIR? Cue Biopharma received 128 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 52.33% of users gave Cue Biopharma an outperform vote while only 47.37% of users gave Atea Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCue BiopharmaOutperform Votes14652.33% Underperform Votes13347.67% Atea PharmaceuticalsOutperform Votes1847.37% Underperform Votes2052.63% Is CUE or AVIR more profitable? Atea Pharmaceuticals has a net margin of 0.00% compared to Cue Biopharma's net margin of -566.02%. Atea Pharmaceuticals' return on equity of -33.24% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Cue Biopharma-566.02% -142.93% -82.85% Atea Pharmaceuticals N/A -33.24%-31.06% SummaryCue Biopharma beats Atea Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUE vs. The Competition Export to ExcelMetricCue BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$78.32M$7.12B$5.36B$8.41BDividend YieldN/A8.77%5.22%4.20%P/E Ratio-1.6616.06131.9317.57Price / Sales9.44258.281,440.1578.36Price / CashN/A50.1639.0633.56Price / Book1.965.674.744.57Net Income-$50.73M$151.16M$115.43M$225.42M7 Day Performance3.21%-1.80%-0.86%-0.61%1 Month Performance112.63%5.92%3.61%1.50%1 Year Performance-23.33%39.97%38.90%32.94% Cue Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CUECue Biopharma4.6209 of 5 stars$1.61-8.0%$5.00+210.6%-8.9%$78.32M$8.30M-1.6660Positive NewsAVIRAtea Pharmaceuticals3.753 of 5 stars$3.35-0.9%$6.88+105.4%+5.8%$284.67M$351.37M-1.6070Short Interest ↓URGNUroGen Pharma4.2565 of 5 stars$12.10flat$48.38+299.8%+19.8%$283.79M$85.01M-3.69200Upcoming EarningsPositive NewsSTROSutro Biopharma4.0521 of 5 stars$3.45-0.3%$12.13+251.4%+38.0%$282.19M$169.36M-1.89240BTMDbiote3.9797 of 5 stars$5.13+2.2%$8.39+63.5%-2.1%$281.94M$185.36M30.18194Short Interest ↓News CoveragePositive NewsPRQRProQR Therapeutics2.8373 of 5 stars$3.46+0.3%$3.38-2.5%+205.0%$281.49M$15.41M-11.93180Upcoming EarningsAnalyst UpgradeHRTXHeron Therapeutics3.653 of 5 stars$1.85+3.9%$6.00+224.3%+185.7%$278.71M$136.36M-5.78300Positive NewsIMMPImmutep1.3228 of 5 stars$1.90+0.5%$8.00+321.1%+6.6%$276.37M$5.14M0.002,021Positive NewsGNFTGenfit1.4651 of 5 stars$5.50-1.6%$13.00+136.4%+86.9%$274.48M$76.06M0.00120Short Interest ↑News CoverageCDXCChromaDex4.3663 of 5 stars$3.47+1.2%$6.00+72.9%+171.2%$262.12M$85.58M-173.50106Short Interest ↓News CoverageEDITEditas Medicine4.6615 of 5 stars$3.18flat$9.91+211.6%-52.3%$261.52M$67.03M-1.35230Upcoming EarningsShort Interest ↑Analyst Revision Related Companies and Tools Related Companies Atea Pharmaceuticals Alternatives UroGen Pharma Alternatives Sutro Biopharma Alternatives biote Alternatives ProQR Therapeutics Alternatives Heron Therapeutics Alternatives Immutep Alternatives Genfit Alternatives ChromaDex Alternatives Editas Medicine Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CUE) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
